Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ImmunityBio

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2014-01-01

Employees: 628

Market Cap: $2.9B

Website: http://www.immunitybio.com

Introduction: ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Clinical Trials

Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis

Phase 1

Recruiting

Conditions: Healthy Subjects

Interventions: Drug: N-803

First Posted Date: 2023-09-18

Last Posted Date: 2024-01-29

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 10

Registration Number: NCT06040918

Locations: 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

Phase 2

Terminated

Conditions: COVID-19

Interventions: Biological: hAd5-S-Fusion+N-ETSD
Biological: Placebo (0.9% (w/v) saline)

First Posted Date: 2023-09-01

Last Posted Date: 2024-06-07

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 35

Registration Number: NCT06022224

Locations: 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting

Conditions: Non Muscle Invasive Bladder Cancer

First Posted Date: 2023-08-08

Last Posted Date: 2025-03-13

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 6

Registration Number: NCT05981131

Locations: 🇺🇸
Island Urology, Honolulu, Hawaii, United States

IBRX-042 In Participants With HPV-Associated Tumors

Phase 1

Recruiting

Conditions: HPV-Related Carcinoma

Interventions: Drug: IBRX-042

First Posted Date: 2023-08-04

Last Posted Date: 2025-05-29

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 12

Registration Number: NCT05976828

Locations: 🇺🇸
Chan Soon-Shiong Institute for Medicine (CSSIFM), El Segundo, California, United States
🇺🇸
Texas Oncology Austin Central, Austin, Texas, United States
🇺🇸
The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Non Hodgkin's Lymphoma Refractory/Relapsed

Interventions: Biological: CD19t-haNK suspension
Drug: N803
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2022-11-16

Last Posted Date: 2024-08-20

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 20

Registration Number: NCT05618925

Locations: 🇺🇸
Hoag Memorial Hospital, Newport Beach, California, United States

THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines

Phase 1

Terminated

Conditions: COVID-19

Interventions: Biological: AAHI-SC2 Vaccine
Biological: AAHI-SC3 Vaccine
Biological: EUA or approved vaccine

First Posted Date: 2022-05-11

Last Posted Date: 2025-03-11

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 60

Registration Number: NCT05370040

Locations: 🇿🇦
Wits Vida, Johannesburg, South Africa

HCW9218 for Advanced Pancreatic Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Pancreatic Carcinoma

Interventions: Drug: HCW9218

First Posted Date: 2022-03-31

Last Posted Date: 2024-12-20

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 60

Registration Number: NCT05304936

Locations: 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸
National Institute of Health/ National Cancer Institute, Bethesda, Maryland, United States
🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States

and more 2 locations

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Phase 1

Terminated

Conditions: Advanced Triple Negative Breast Cancer

Interventions: Biological: N-803
Biological: PD-L1 t-haNK
Drug: Sacituzumab Govitecan-Hziy
Drug: Cyclophosphamide

First Posted Date: 2021-06-16

Last Posted Date: 2024-06-12

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 3

Registration Number: NCT04927884

Locations: 🇺🇸
Hoag Memorial Hospital, Newport Beach, California, United States

QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Solid Tumor

Interventions: Other: Apheresis collection of MNCs (part A)
Biological: M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)
Biological: N-803 (Cohort 2 part B)

First Posted Date: 2021-05-24

Last Posted Date: 2025-05-09

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 50

Registration Number: NCT04898543

Locations: 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines

Phase 1

Withdrawn

Conditions: Covid19

Interventions: Biological: hAd5-S-Fusion+N-ETSD vaccine

First Posted Date: 2021-04-14

Last Posted Date: 2025-02-21

Lead Sponsor: ImmunityBio, Inc.

Registration Number: NCT04845191

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy